Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Expression in Core Needle Biopsy Diagnoses Breast Cancer

By HospiMedica staff writers
Posted on 28 Aug 2006
The gene-expression profile detected in a core needle biopsy of a breast tumor is representative of gene expression in the whole tumor and therefore a reliable diagnostic for breast cancer, according to a new study.

The study, published in the August 2006 edition of the journal Breast Cancer Research, confirms the reliability of core needle biopsy as a tool in breast-cancer diagnosis and prognosis. More...
The study also shows that the gene expression profile of a core needle biopsy might be more accurate than the profile of a surgical sample taken from the same tumor after the biopsy was carried out. According to the study results, the biopsy procedure triggers the expression of genes involved in wound healing as well as tumor invasion and metastasis, thus modifying the gene expression profile of subsequent surgical samples.

Dr. Rosanna Zanetti-Dällenbach, from the Women's University Hospital (Basel, Switzerland), and colleagues analyzed the gene expression profile of core needle biopsies taken from 22 women diagnosed with breast cancer. For each woman, they compared the biopsy expression profile with the expression profile of a surgical sample taken from the tumor subsequent to the core needle biopsy. They quantified the expression of 60 genes known to be involved in breast tumor development using reverse transcription polymerase chain reaction (RT-PCR). Dr. Zanetti-Dällenbach and colleagues also analyzed the gene expression profiles of surgical samples taken from breast tumors of 317 patients who did not undergo a core needle biopsy.

The results of the study showed that the gene expression levels of the core biopsy and the surgical sample are identical for most women. However, the expression of four specific genes was significantly increased in the surgical samples compared to the core needle biopsies. In the group of women who did not get a core needle biopsy, however, the expression of these four genes was not increased. These four genes are involved in inflammation and wound repair as well as tumor invasion and metastasis. The authors conclude that their expression must therefore be modified by the core needle biopsy procedure itself and they warn that care should be taken when interpreting the gene expression profile of a surgical sample carried out following a core biopsy.



Related Links:
Women's U. Hospital

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.